TCGA-OL-A5DA-01A-11R-A27Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 59
- os_event
- false
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A43X-01A-11R-A23W-07 | — | — | 0.925 |
| 2 | C3N-03420 | — | cohortA1 | 0.881 |
| 3 | MDT-AP-1160 | Med | Medulloblastoma | 0.880 |
| 4 | SRR1516072 | — | — | 0.878 |
| 5 | MNG851 | — | — | 0.877 |
| 6 | ea635e80-1225-4f52-a6cf-8f4c20201240 | — | — | 0.874 |
| 7 | SRR1516050 | — | — | 0.874 |
| 8 | AUR-AFE5-TTM9-A-1-1-R-A742-41 | — | D | 0.871 |
| 9 | R87 | — | — | 0.870 |
| 10 | SRR1516063 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |